Apex Labs Ltd

APEX is a patient-driven pharmaceutical company focused on optimizing the standard of mental health care with psilocybin by bringing data supported, clinically evaluated drugs to market for depression and anxiety in PTSD. Our strategy is focused on developing pharmaceutical products through a phased clinical program evaluating safety and efficacy across multiple indications, alongside a robust early access program. APEX has two GMP Certified drug assets. APEX-52 is microdose synthetic psilocybin for clinical evaluation, currently in active phase 2b trials, and APEX-25 is the companys macro dose drug asset, developed for in-clinic dosing with assisted psychotherapy. APEX recently launched North Americas...

Pharmaceuticals,drug development,psychedelics,psilocybin,psilocin,laboratory,clinical trials,research and development,ketamine,mdma,psychotherapy,section 56(1) exemptions,dealer's licence,dmt,lsd,finance,public markets,capital markets,neo exchange,veterans,first responders,ptsd,depression,and mental disorders

Apex labs ltd operates in the Pharmaceutical manufacturing industry.

Apex labs ltd's revenue is 11m - 100m

Apex labs ltd has 11 - 50 employees.